RVTY

Revvity, Inc.

September 24, 2026 · intraday

Rarity

1.49

Peak move

+6.73%

Float cap

$15.9B

Revvity, Inc. provides health science solutions, technologies, expertise, and services that support workflows from discovery to development and diagnosis to cure. It operates in Life Sciences and Diagnostics, offering reagents, assays, software, and services for cell, gene, and protein research. Its customers include global pharmaceutical, biotechnology, and contract research organizations, as well as academic and government institutions.

• institutional_flowSep 24 · 03:45 ET

  State Street Corp increased its Revvity stake by 32,426 shares (0.8%) in Q2 to 4,342,739 shares worth about $483.2 million, or 3.89% of the company, per its latest 13F disclosed September 24, 2026.

  Webmarketbeat.com
• Key eventproduct_launchSep 24

  Revvity launched the GSP T1D 3plex kit, a fully automated CE-IVDR-certified multiplex autoantibody detection solution using dried blood spots on its GSP instrument for population-wide type 1 diabetes screening, initially available in Europe and CE IVD-marked markets but not FDA-cleared.

  Webnews.revvity.comWebir.revvity.com
• peer_disclosureSep 24

  Biodesix outlined two molecular residual disease programs: a tumor-informed assay with Bio-Rad using Droplet Digital PCR detecting ctDNA below 1 part per million, and a newly launched tumor-naïve program with Thermo Fisher Scientific running methylated ctDNA on its Genexus NGS platform.

  Webvaluespectrum.com
• Key eventinsider_saleSep 23 · 16:05 ET

  Revvity CFO Maxwell Krakowiak sold 1,631 shares at $144.53 per share for about $235,728 on September 21, 2026 under a Rule 10b5-1 plan adopted May 19, 2026, leaving him 14,781 shares, per a Form 4 filed September 23, 2026.

  SEC4 0001193125-26-399376Websec.govWebmarketbeat.comWebsec.govWebkalkine.com
• Key eventpeer_disclosureSep 23

  Bio-Techne shareholders voted to approve the definitive merger agreement under which Merck KGaA will acquire the life sciences tools and diagnostics company, with the HSR waiting period expired September 18, 2026 and closing expected late 2026 or early 2027.

  Webmarketscreener.com
• acquisition_acquirerSep 21

  Revvity signed a definitive agreement to acquire France-based Human Cell Design, adding its EndoC-βH5 human pancreatic beta cell model and NatLine platform to Revvity's Life Sciences portfolio for GLP-1 and GPCR metabolic disease drug discovery, with undisclosed terms and expected close in Q4 2026.

  Webmobile.aktien-mag.de
• insider_saleSep 21

  Revvity Senior Vice President, Global Operations Tajinder S. Vohra sold 7,330 shares at $140.88 per share ($1,032,650) on September 16, 2026, a 52.49% decrease in his position leaving 6,635 shares, per a Form 4 filed September 18, 2026.

  Webbasic.10jqka.com.cn